- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07905183
A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs (ENABLE-2)
A Phase 3, Multicenter, Open-Label, Randomized Study of ELVN-001 Versus Investigator-Selected Tyrosine Kinase Inhibitor (TKI) of Dasatinib, Nilotinib, or Bosutinib, in Adult Participants With Chronic Myeloid Leukemia in Chronic Phase (CP-CML), Previously Treated With One or More TKIs
The study is designed to compare the efficacy of ELVN-001 versus Investigator-selected tyrosine kinase inhibitor (TKI) for adults with previously treated chronic myeloid leukemia in the chronic phase (CP-CML). The Investigator-selected TKI will be one of the following standard of care therapies: Dasatinib, Nilotinib, or Bosutinib.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This is a multicenter, open-label, randomized study of ELVN-001 versus Investigator-selected TKI (Dasatinib, Nilotinib, or Bosutinib) in adult participants with CP-CML previously treated with one or more TKIs. Participants will be randomized to receive either ELVN-001 or their investigator's choice of one of the comparator TKIs (Dasatinib, Nilotinib, or Bosutinib). Treatment will continue until one of the protocol defined treatment discontinuation criteria are met. Participants will then enter a long-term follow-up period for survivorship and updates on disease status.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 3
Kontakte und Standorte
Studienkontakt
- Name: Enliven Medical Information
- Telefonnummer: +1 6505475814
- E-Mail: MedInfo@enliventherapeutics.com
Studienorte
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30322
- Rekrutierung
- Winship Cancer Institute
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46260
- Rekrutierung
- Investigative Clinical Research of Indiana, LLC
-
-
New Jersey
-
Morristown, New Jersey, Vereinigte Staaten, 07960
- Rekrutierung
- Atlantic Health System
-
-
Utah
-
Ogden, Utah, Vereinigte Staaten, 84405
- Rekrutierung
- Community Center Trials of Utah
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male or female at least 18 years of age
- Diagnosis of chronic myeloid leukemia in chronic phase (CP-CML)
- Prior treatment with 1 or more BCR::ABL1 TKI(s)
- Failure or intolerance on the immediate prior TKI
- Adequate end organ function as measured by blood tests
Exclusion Criteria:
- Known T315I mutation
- Known second chronic phase of CML after previous progression to accelerated or blast phase
- Any serious or uncontrolled medical disorder
- QT interval corrected by Fridericia's formula (QTcF) ≥ 470 msec
- Previous treatment with a hematopoietic stem-cell transplantation
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: ELVN-001
ELVN-001 |
ELVN-001 orally daily |
|
Aktiver Komparator: Investigator-selected TKI
Randomized to receive one of the following investigator's choice TKIs: Dasatinib, Nilotinib, or Bosutinib |
TKI orally daily
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Major Molecular Response (MMR) Rate at Week 24 - ELVN-001 versus Investigator-selected TKI
Zeitfenster: 24 weeks
|
Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale. |
24 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Major Molecular Response (MMR) Rate at Week 96 - ELVN-001 versus Investigator-selected TKI
Zeitfenster: 96 weeks
|
Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale. |
96 weeks
|
|
Change in overall scores, individual scales, and health status based on participant reporting - ELVN-001 versus Investigator-selected TKI
Zeitfenster: planned total follow-up duration of 5 years
|
Validated questionnaires will be used to assess disease-related symptoms, functioning, and tolerability. |
planned total follow-up duration of 5 years
|
|
Major Molecular Response (MMR) at all scheduled collection time points - ELVN-001 versus Investigator-selected TKI
Zeitfenster: planned total follow-up duration of 5 years
|
Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale |
planned total follow-up duration of 5 years
|
|
Major Molecular Response (MMR) by all scheduled collection time points - ELVN-001 versus Investigator-selected TKI
Zeitfenster: planned total follow-up duration of 5 years
|
Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MMR is defined as a ratio BCR::ABL/ABL1 ≤ 0.1% on the International Scale |
planned total follow-up duration of 5 years
|
|
Time to Major Molecular Response (MMR) - ELVN-001 versus Investigator-selected TKI
Zeitfenster: planned total follow-up duration of 5 years
|
The time to MMR is defined as the time from the date of randomization to the date of the first documented occurrence of MMR |
planned total follow-up duration of 5 years
|
|
Duration of Major Molecular Response (MMR) - ELVN-001 versus Investigator-selected TKI
Zeitfenster: planned total follow-up duration of 5 years
|
Duration of MMR is defined as the time between the date of the first achievement of MMR and the earliest date of loss of MMR or CML-related death |
planned total follow-up duration of 5 years
|
|
BCR::ABL1 ratio ≤ 1% at and by all scheduled data collection time points - ELVN-001 versus Investigator-selected TKI
Zeitfenster: planned total follow-up duration of 5 years
|
BCR::ABL1 transcript levels are measured by quantitative polymerase chain reaction (qPCR). The ratio is calculated for BCR::ABL/ABL1 based on the International Scale |
planned total follow-up duration of 5 years
|
|
Time to treatment failure - ELVN-001 versus Investigator-selected TKI
Zeitfenster: planned total follow-up duration of 5 years
|
Time to treatment failure is defined as the time from randomization to the first date of any of the following events: treatment failure as defined per protocol |
planned total follow-up duration of 5 years
|
|
Progression-free survival - ELVN-001 versus Investigator-selected TKI
Zeitfenster: planned total follow-up duration of 5 years
|
Progression-free survival is defined as the time from randomization to the earliest occurrence of progression or death from any cause |
planned total follow-up duration of 5 years
|
|
Overall survival (OS) - ELVN-001 versus Investigator-selected TKI
Zeitfenster: planned total follow-up duration of 5 years
|
OS is defined as the time from randomization to death from any cause |
planned total follow-up duration of 5 years
|
|
MR4 and MR4.5 at and by all scheduled data collection time points - ELVN-001 versus Investigator-selected TKI
Zeitfenster: planned total follow-up duration of 5 years
|
Molecular response is assessed using BCR::ABL1 transcript levels measured by quantitative polymerase chain reaction (qPCR). MR4 is defined as a ratio BCR::ABL/ABL1 ≤ 0.01% on the International Scale and MR4.5 is defined as a ratio BCR::ABL/ABL1 ≤ 0.0032% on the International Scale |
planned total follow-up duration of 5 years
|
|
Time to treatment discontinuation due to adverse event (AE) - ELVN-001 versus Investigator-selected TKI
Zeitfenster: planned total follow-up duration of 5 years
|
This is defined as the time from randomization to discontinuation of study treatment due to an adverse event |
planned total follow-up duration of 5 years
|
|
Characterization of adverse events (AE) and clinically relevant findings, including laboratory abnormalities, electrocardiogram (ECG) changes, and other safety data - ELVN-001 versus Investigator-selected TKI
Zeitfenster: planned total follow-up duration of 5 years
|
Characteristics of AEs will be evaluated to assess safety and tolerability profiles |
planned total follow-up duration of 5 years
|
|
Plasma concentrations of ELVN-001 in participants treated with ELVN-001 will be assessed at all scheduled collection timepoints
Zeitfenster: planned total follow-up duration of 5 years
|
Relevant pharmacokinetic parameters will be evaluated |
planned total follow-up duration of 5 years
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Neubildungen
- Chronische Erkrankung
- Krankheitsattribute
- Neubildungen nach histologischem Typ
- Hämatologische Erkrankungen
- Leukämie, Myeloid
- Erkrankungen des Knochenmarks
- Leukämie
- Myeloproliferative Erkrankungen
- Translokation, Genetik
- Chromosomenaberrationen
- Pathologische Zustände, Anzeichen und Symptome
- Hämische und lymphatische Krankheiten
- Leukämie, myeloische, chronische, BCR-ABL-positiv
- Philadelphia-Chromosom
- Leukämie, myeloische, chronische Phase
- Schwefelverbindungen
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Thiazoles
- Azolen
- Pyrimidine
- Dasatinib
- Nilotinib
- Bosutinib
Andere Studien-ID-Nummern
- ELVN-001-301
- 2026-526266-25-00 (Ctis)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .